References 589 & 647. Heydarzadeh S, Moshtaghie AA, Daneshpoor M, Hedayati M. Regulators of glucose uptake in thyroid cancer cell lines. Cell Commun Signal. 2020;18:83. https://doi.org/10.1186/s12964-020-00586-x. 648. Matsuura D, Yuan A, Wang LY, Ranganath R, Adilbay D, Harries V, et al. Follicular and hurthle cell carcinoma: comparison of clinicopathological features and clinical outcomes. Thyroid. 2022;32:245-254. https://doi. org/10.1089/thy.2021.0424. 649. Corver WE, Demmers J, Oosting J, Sahraeian S, Boot A, Ruano D, et al. ROS-induced near-homozygous genomes in thyroid cancer. Endocrine-related cancer. 2018;25:83-97. https://doi.org/10.1530/ERC-17-0288. 650. Strieder DL, Cristo AP, Zanella AB, Faccin CS, Farenzena M, Graudenz MS, et al. Using an ultrasonography risk stratification system to enhance the thyroid fine needle aspiration performance. Eur J Radiol. 2022;150:110244. https://doi.org/10.1016/j.ejrad.2022.110244. 651. de Koster EJ, de Geus-Oei LF, Dekkers OM, van Engen-van Grunsven I, Hamming J, Corssmit EPM, et al. Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. Endocr Rev. 2018;39:154191. https://doi.org/10.1210/er.2017-00133. 652. Joensuu H, Ahonen A, Klemi PJ. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med. 1988;13:502-506. https://doi.org/10.1007/BF00256624. 653. Adler LP, Bloom AD. Positron emission tomography of thyroid masses. Thyroid. 1993;3:195-200. https://doi. org/10.1089/thy.1993.3.195. 654. Bloom AD, Adler LP, Shuck JM. Determination of malignancy of thyroid nodules with positron emission tomography. Surgery. 1993;114:728-734; discussion 734-725. 655. Salvatori M, Biondi B, Rufini V. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/ computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and followup. Eur J Endocrinol. 2015;173:R115-130. https://doi.org/10.1530/EJE-15-0066. 656. Pak K, Kim SJ, Kim IJ, Kim BH, Kim SS, Jeon YK. The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery. Endocr Relat Cancer. 2013;20:R203-213. https://doi.org/10.1530/ERC13-0088. 657. Wang N, Zhai H, Lu Y. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? A meta-analysis of the literature. J Otolaryngol Head Neck Surg. 2013;42:38. https://doi.org/10.1186/1916-0216-42-38. 658. Castellana M, Trimboli P, Piccardo A, Giovanella L, Treglia G. Performance of (18)F-FDG PET/CT in Selecting Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytology for Surgery. A Systematic Review and a Meta-Analysis. J Clin Med. 2019;8. https://doi.org/10.3390/jcm8091333. 659. Qichang W, Jinming S, Lu L, Bin J, Renjie W, Xiuying Z. Comparison of 18F-FDG-PET and 18F-FDG-PET/CT for the diagnostic performance in thyroid nodules with indeterminate cytology: A meta-analysis. Medicine (Baltimore). 2020;99:e20446. https://doi.org/10.1097/MD.0000000000020446. 660. Scappaticcio L, Piccardo A, Treglia G, Poller DN, Trimboli P. The dilemma of (18)F-FDG PET/CT thyroid incidentaloma: what we should expect from FNA. A systematic review and meta-analysis. Endocrine. 2021;73:540-549. https://doi. org/10.1007/s12020-021-02683-4. 661. de Koster EJ, de Geus-Oei LF, Brouwers AH, van Dam E, Dijkhorst-Oei LT, van Engen-van Grunsven ACH, et al. [(18)F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. Eur J Nucl Med Mol Imaging. 2022;49:1970-1984. https://doi.org/10.1007/s00259-021-05627-2. 662. de Koster EJ, Noortman WA, Mostert JM, Booij J, Brouwer CB, de Keizer B, et al. Quantitative classification and radiomics of [(18)F]FDG-PET/CT in indeterminate thyroid nodules. Eur J Nucl Med Mol Imaging. 2022;49:2174-2188. https://doi.org/10.1007/s00259-022-05712-0. 663. de Koster EJ, Vriens D, van Aken MO, Dijkhorst-Oei LT, Oyen WJG, Peeters RP, et al. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial. Eur J Nucl Med Mol Imaging. 2022;49:3452-3469. https://doi.org/10.1007/s00259-022-05794-w. 664. de Koster EJ, Husson O, van Dam E, Mijnhout GS, Netea-Maier RT, Oyen WJG, et al. Health-related quality of life following FDG-PET/CT for cytological indeterminate thyroid nodules. Endocr Connect. 2022;11. https://doi. org/10.1530/EC-22-0014. 665. de Koster EJ, van Engen-van Grunsven ACH, Bussink J, Frielink C, de Geus-Oei LF, Kusters B, et al. [(18)F]FDG Uptake and Expression of Immunohistochemical Markers Related to Glycolysis, Hypoxia, and Proliferation in Indeterminate Thyroid Nodules. Mol Imaging Biol. 2022. https://doi.org/10.1007/s11307-022-01776-4. 666. Thuillier P, Benisvy D, Ansquer C, Corvilain B, Mirallie E, Taieb D, et al. Section 5: What is the role of functional imaging and isotopic treatment? Ann Endocrinol (Paris). 2022. https://doi.org/10.1016/j.ando.2022.10.008. 667. Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS. The Diagnosis and Management of Thyroid Nodules: A Review. JAMA. 2018;319:914-924. https://doi.org/10.1001/jama.2018.0898.
RkJQdWJsaXNoZXIy MTk4NDMw